Areteia Therapeutics is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies that put respiratory patients in better control of their disease and back in control of their lives. Our initial focus is developing the first potential oral drug for severe eosinophilic asthma.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/13/24 | $75,000,000 | Series A |
Access Biotechnology ARCH Venture Partners Bain Capital Life Sciences  GV Marshall Wace Maverick Capital Population Health Partners Sanofi Saturn Partners Viking Global Investors | undisclosed |
